Onconic Therapeutics said it has been officially invited to participate in the J.P. Morgan Healthcare Conference 2025, set to take place from Jan. 13 to 16, in San Francisco, U.S.

As the world’s largest pharmaceutical and biotech investment conference, the annual event will host over 550 companies and attract more than 8,000 investors and industry professionals this year.

The company stressed that the invitation to the conference shows the growing global recognition for its innovative drug research and development capabilities, coming shortly after its listing on the Kosdaq market.

Onconic Therapeutics is known for its success in commercializing Jaqbo, a P-CAB (potassium-competitive acid blocker)-based treatment for gastroesophageal reflux disease, which became Korea’s 37th locally developed new drug. The company has received approval for Jaqbo in 21 countries, including China and India.

The company is also advancing the development of nesuparib, a synthetic lethality-based anticancer drug candidate.

Nesuparib has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for pancreatic cancer and is currently undergoing phase 2 clinical trials in combination with Keytruda (ingredient: pembrolizumab).

During the J.P. Morgan Healthcare Conference, Onconic stressed that it plans to hold strategic meetings with global pharmaceutical companies and investors.

“This conference will serve as a pivotal opportunity to showcase Onconic Therapeutics’ innovative drug pipeline and technological capabilities to the global market while fostering new collaborations,” a company official said. “Given that nesuparib’s market value was excluded from our IPO pricing to benefit new shareholders, we expect this event to initiate a significant reassessment of our corporate value and drive substantial growth.”